IPO registrations (S-1, F-1) · Registrants
KAMADA LTD
- SEC CIK
- 1567529 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2013-04-11, last 2013-05-28; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2013-05-31; declared effective 2013-05-30
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- L3
- Business address
- 2 HOLTZMAN ST., SCIENCE PARK, Rehovot, L3 7670402
- Ticker
- KMDA (Nasdaq)
- EDGAR entity type
- other
- Insiders and CEO pay
- KAMADA LTD on the corporate pages
Offering terms
- Final price
- $9.25 per share (424B4 filed 2013-05-31, an initial public offering)
- Shares sold
- 5,582,636
- Gross proceeds
- $51,639,383 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol KMDA
- Lead underwriters
- Morgan Stanley; Jefferies
- Syndicate
- RBC Capital Markets; Oppenheimer
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: KAMADA LTD EXACT (CIK (EXACT))
Filings 5
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-04-11 | F-1 | F-1 (foreign registration) | KAMADA LTD | 0001144204-13-021368 ↗ |
| 2013-05-15 | F-1/A | F-1/A (amendment) | KAMADA LTD | 0001144204-13-029602 ↗ |
| 2013-05-28 | F-1/A | F-1/A (amendment) | KAMADA LTD | 0001144204-13-031877 ↗ |
| 2013-05-30 | EFFECT | EFFECT (declared effective) | KAMADA LTD | 9999999995-13-001666 ↗ |
| 2013-05-31 | 424B4 | 424B4 (final prospectus) | KAMADA LTD | 0001144204-13-032683 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2013-05-28 | F-1/A | registration statement | 5,582,636 | - | Nasdaq KMDA | 5 | primary document; shares headline, cover names 5 | document ↗ | ||
| 2013-05-31 | 424B4 | final prospectus | $9.25 | 5,582,636 | $51,639,383 | Nasdaq KMDA | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Livneh Nir | Officer | VP, General Counsel | 4 | 2026 | |
| Beladev Shavit | Officer | VP Plasma Operations | 3 | 2026 | |
| Brenner Yael | Officer | VP Quality | 6 | 2026 | |
| Dekel Benjamin | Director | 4 | 2026 | ||
| Goldwasser Karnit | Director | 4 | 2026 | ||
| Gorelik Boris | Officer | VP, BD and Strategic Programs | 3 | 2026 | |
| ITSHAYEK ASSAF | Director | 4 | 2026 | ||
| Knight Jon | Officer | Vice President, US Commercial | 1 | 2026 | |
| London Amir | Officer | Chief Executive Officer | 3 | 2026 | |
| Neheman Hanni | Officer | VP, Marketing & Sales | 3 | 2026 | |
| Nir Eran | Officer | Vice President, Operations; VP, Operations | 3 | 2026 | |
| ORLEV CHAIME | Officer | Chief Financial Officer | 3 | 2026 | |
| Pinchuk Orit | Officer | VP Regulatory Affairs | 3 | 2026 | |
| RECANATI LEON | Director | 4 | 2026 | ||
| Reshef Liron | Officer | VP Human Resources | 3 | 2026 | |
| Tsur David | Director | 7 | 2026 | ||
| Payorski Lilach | Director | 4 | 2026 | ||
| DAVIDI ISHAY | Director,TenPercentOwner | 4 | 2026 | ||
| Asher-Topilsky Lilach | Director | 3 | 2026 | ||
| Botzer Uri | Director | 3 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | KAMADA LTD | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, L3 first:
- CANNAPOWDER, INC. L3
- Rosetta Genomics Ltd. L3
- BIOCANCELL THERAPEUTICS INC. L3
- Can-Fite BioPharma Ltd. L3
- RedHill Biopharma Ltd. L3
- MAPI - PHARMA LTD L3
- NeuroDerm Ltd. L3
- Advanced Inhalation Therapies (AIT) Ltd. L3
- Silenseed Ltd. L3
- SciSparc Ltd. L3
In other datasets, the same topic (Health) in L3:
- Form D issuer: Agada Medical Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health